U.S. patent application number 11/038933 was filed with the patent office on 2005-12-22 for immunization for ebola virus infection.
Invention is credited to Nabel, Gary J., Sanchez, Anthony.
Application Number | 20050281844 11/038933 |
Document ID | / |
Family ID | 34118119 |
Filed Date | 2005-12-22 |
United States Patent
Application |
20050281844 |
Kind Code |
A1 |
Nabel, Gary J. ; et
al. |
December 22, 2005 |
Immunization for Ebola virus infection
Abstract
Ebola virus vaccines comprising nucleic acid molecules encoding
Ebola viral proteins are provided. In one embodiment, the nucleic
acid molecule encodes the transmembrane form of the viral
glycoprotein (GP). In another embodiment, the nucleic acid molecule
encodes the secreted form of the viral glycoprotein (sGP). In yet
another embodiment, the nucleic acid molecule encodes the viral
nucleoprotein (NP). Methods for immunizing a subject against
disease caused by infection with Ebola virus are also provided.
Inventors: |
Nabel, Gary J.; (Washington,
DC) ; Sanchez, Anthony; (Atlanta, GA) |
Correspondence
Address: |
KNOBBE, MARTENS, OLSON & BEAR, LLP
2040 MAIN STREET
FOURTEENTH FLOOR
IRVINE
CA
92614
US
|
Family ID: |
34118119 |
Appl. No.: |
11/038933 |
Filed: |
January 19, 2005 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
11038933 |
Jan 19, 2005 |
|
|
|
09913909 |
Aug 17, 2001 |
|
|
|
6852324 |
|
|
|
|
09913909 |
Aug 17, 2001 |
|
|
|
PCT/US98/27364 |
Dec 23, 1998 |
|
|
|
60068655 |
Dec 23, 1997 |
|
|
|
Current U.S.
Class: |
424/204.1 ;
514/44R |
Current CPC
Class: |
A61K 2039/53 20130101;
C12N 2760/14122 20130101; C07K 14/005 20130101 |
Class at
Publication: |
424/204.1 ;
514/044 |
International
Class: |
A61K 048/00; A61K
039/12 |
Claims
1. (canceled)
2. (canceled)
3. The pharmaceutical composition of claim 8, wherein the control
sequence is a promoter.
4. The pharmaceutical composition of claim 3, wherein the promoter
is the CMV immediate-early region 1 promoter.
5. The pharmaceutical composition of claim 8, further comprising an
adjuvant.
6. (canceled)
7. (canceled)
8. A pharmaceutical composition comprising a nucleic acid molecule
encoding an Ebola virus structural gene product operatively-linked
to a heterologous control sequence, in a pharmaceutically
acceptable carrier, wherein the Ebola virus structural gene product
is virus nucleoprotein.
9. A method of producing a vaccine against disease caused by
infection by Ebola virus, comprising the steps of: a) administering
the pharmaceutical composition of claim 8 to a test host to
determine an amount and a frequency of administration thereof to
elicit a protective immune response in said host; and b)
formulating said pharmaceutical composition in a form suitable for
administration to a treatable host in accordance with said
determined amount and frequency of administration.
10. (canceled)
11. (canceled)
12. (canceled)
13. (canceled)
14. (canceled)
15. (canceled)
16. (canceled)
17. (canceled)
18. A vaccine comprising a nucleic acid molecule encoding the Ebola
virus nucleoprotein operatively-linked to a heterologous control
sequence, in a pharmaceutically acceptable carrier.
19. The vaccine of claim 18, wherein the control sequence is a
promoter.
20. The vaccine of claim 19, wherein the promoter is the CMV
immediate-early region 1 promoter.
21. The vaccine of claim 18, further comprising an adjuvant.
22. (canceled)
23. A method of immunizing a subject against hemorrhagic fever
comprising the step of administering to the host an immunoeffective
amount of the vaccine of any of claims 18 to 21, wherein the
hemorrhagic fever is caused by infection with Ebola virus.
24. (canceled)
25. The method of claim 23, wherein the host is a human and
administration is by intramuscular injection.
26. The method of claim 23, wherein the subject receives a second
administration of an immunoeffective amount of a vaccine against
disease caused by infection by Ebola virus.
Description
FIELD OF THE INVENTION
[0001] The present invention relates generally to viral vaccines
and, more particularly, to Ebola virus vaccines and methods of
protecting against disease caused by infection with Ebola
virus.
BACKGROUND OF THE INVENTION
[0002] The Ebola viruses, and the genetically-related Marburg
virus, are filoviruses associated with outbreaks of highly lethal
hemorrhagic fever in humans and primates in North America, Europe,
and Africa. Peters, C. J. et al., Filoviridae: Marburg and Ebola
Viruses. in Fields Virology. (eds., Fields, B. N., Knipe, D. M.
& Howley, P. M.) 1161-1176 (Philadelphia, Lippincott-Raven,
1996); Peters, C. J. et al, Semin. Virol. 5:147-154 (1994). Ebola
viruses are negative-stranded RNA viruses comprised of four
subtypes, including those described in the Zaire, Sudan, Reston,
and Ivory Coast episodes. Sanchez, A. et al., PNAS (USA)
93:3602-3607 (1996). Although several subtypes have been defined,
the genetic organization of these viruses is similar, each
containing seven linearly arrayed genes. Among the viral proteins,
the envelope glycoprotein exists in two alternative forms, a 50-70
kilodalton (kDa) secreted protein of unknown function encoded by
the viral genome and a 130 kDa transmembrane glycoprotein generated
by RNA editing that mediates viral entry. Peters, C. J. et al.,
Filoviridae: Marburg and Ebola Viruses. in Fields Virology. (eds.,
Fields, B. N., Knipe, D. M. & Howley, P. M.) 1161-1176
(Philadelphia, Lippincott-Raven, 1996); Sanchez, A. et al., PNAS
(USA) 93:3602-3607 (1996). Other structural gene products include
the nucleoprotein (NP), matrix proteins VP24 and VP40, presumed
nonstructural proteins VP30 and VP35, and the viral polymerase
(reviewed in Peters, C. J. et al., Filovirdae: Marburg and Ebola
Viruses. in Fields Virology. (eds., Fields, B. N., Knipe, D. M.
& Howley, P. M.) 1161-1176 (Philadelphia, Lippincott-Raven,
1996)). Although spontaneous variation of its RNA sequence does
occur in nature, there appears to be less nucleotide polymorphism
within Ebola subtypes than among other RNA viruses (Sanchez, A. et
al., PNAS (USA) 93:3602-3607 (1996)), suggesting that immunization
may be useful in protecting against this disease. Previous attempts
to elicit protective immune responses against Ebola virus using
traditional active and passive immunization approaches have,
however, not succeeded. Peters, C. J. et al., Filoviridae: Marburg
and Ebola Viruses. in Fields Virology. (eds., Fields, B. N., Knipe,
D. M. & Howley, P. M.) 1161-1176 (Philadelphia,
Lippincott-Raven, 1996); Clegg, J. C. S. et al., New Generation
Vaccines. (eds., Levine, M. M., Woodrow, G. C., Kaper, J. B. &
Cobon, G. S.) 749-765 (New York, N.Y., Marcel Dekker, Inc. 1997);
Jahrling, P. B. et al., Arch. Virol. Suppl. 11:135-140 (1996).
[0003] It would thus be desirable to provide a vaccine to protect
against disease caused by infection with Ebola virus. It would
further be desirable to provide methods of making and using said
vaccine.
SUMMARY OF THE INVENTION
[0004] Ebola virus vaccines comprising nucleic acid molecules
encoding Ebola viral proteins are provided. In one embodiment, the
nucleic add molecule encodes the transmembrane form of the viral
glycoprotein (GP). In another embodiment, the nucleic acid molecule
encodes the secreted form of the viral glycoprotein (sGP). In yet
another embodiment, the nucleic acid molecule encodes the viral
nucleoprotein (NP).
[0005] The present invention also provides methods for immunizing a
subject against disease caused by infection with Ebola virus
comprising administering to the subject an immunoeffective amount
of an Ebola virus vaccine. Administration can be by any of the
routes normally used for gene therapy. In a preferred method, the
Ebola virus vaccine is administered by intramuscular injection. The
genetic immunization methods of the present invention provide
protective immunity against disease caused by infection with Ebola
virus.
[0006] Additional objects, advantages, and features of the present
invention will become apparent from the following description and
appended claims, taken in conjunction with the accompanying
drawings.
BRIEF DESCRIPTION OF THE DRAWINGS
[0007] The various advantages of the present invention will become
apparent to one skilled in the art by reading the following
specification and subjoined claims and by referencing the following
drawings.
[0008] FIGS. 1A and 1B are photographs showing expression of Ebola
virus gene products in eukaryotic plasmid expression vectors.
[0009] FIG. 1A. Expression vectors encoding the indicated viral
gene products under regulation of the CMV immediate-early region 1
enhancer and promoter were prepared and transfected into 293 cells
as previously described. Manthorpe, M. et al. Hum. Gene. Ther.
4:419-431 (1993); Sambrook, J., Fritch, E. F., & Maniatis, T.
Cold Spring Harbor, N.Y. Cold Spring Laboratory Harbor Press, 1994.
Cell extracts were prepared and analyzed by Western blot analysis
for NP (left) or GP (right) using relevant rabbit antisera and a
secondary antibody, horseradish peroxidase conjugated donkey
anti-rabbit IgG of a dilution of 1:5,000. Incubation with primary
antibody was for 30 minutes at mom temperature, and for 30 minutes
at room temperature with secondary antibody. Immunocomplexes were
then detected by chemiluminescence using super signal substrate
reagents (Pierce) according to manufacturer's instructions.
[0010] FIG. 1B. Generation of antibody response in mice immunized
with the indicated vectors and analyzed by Western blot for NP, GP,
and sGP as shown. Antisera from mice were tested at a dilution of
1:500 (NP), 1:50 (GP), or 1:50 (sGP), respectively, and developed
with a secondary antibody (sheep anti-mouse, 1:5,000, Amersham Life
Science) and chemiluminescence as in FIG. 1A. The control vector
used for immunization represents the expression vector plasmid with
no insert. Manthorpe, M. et al., Hum. Gene. Ther. 4:419-431
(1993).
[0011] FIGS. 2A-2D are graphs showing the immune responses to NP
and GP after genetic immunization in mice.
[0012] FIG. 2A. Splenic lymphocytes: from vector or NP-plasmid
immunized mice were isolated approximately 6 weeks after the
initial immunization and sensitized in vitro for 5 days with 10
U/ml hlL-2. Renca-NP cells sensitized splenocytes from
vector-immunized or pCMV-NP immunized mice were used to detect CTL
activity at the indicated effector target ratios on Renca or
Renca-NP cells (left, middle) or with allogeneic effector cells
with Renca-NP to show that they are susceptible to lysis (right).
Allogeneic effector cells were generated by incubating cells
derived from mice with a C57BI/6 background (5.times.10.sup.6/ml)
with irradiated Balb/c spleen cells (5.times.10.sup.6/ml) in the
presence of IL-2 (20 U/ml) for five days. The chromium release CTL
assay with Renca-NP cells was performed in triplicate as previously
described. Ohno, T. et al., Gene. Ther. 4:361-366 (1997).
[0013] FIG. 2B. Balb/C female mice were immunized with the sGP
plasmid expression vector and analyzed for their ability to lyse
the syngeneic Renca cell line stably expressing GP. Isolation of
stable transfectants, confirmation of expression, and CTL assay
were performed as described (see, Specific Example, II. Methods).
Renca-GP or sGP sensitized splenocytes from pCMV-GP or pCMV-sGP
immunized mice were used to determine the specific killing of
.sup.51chromium labeled Renca-GP cells at the indicated E/T
ratios.
[0014] FIG. 2C. Mice immunized with GP were analyzed for their
ability to lyse a syngeneic CT26 cell stably expressing GP or CT26
vector control transduced line at the indicated E/T ratios.
[0015] FIG. 2D. Cellular proliferative response in the indicated
immunized mice. T cells, enriched or depleted (see, Specific
Example, II. Methods), were incubated at 10.sup.5 cells/ml with sGP
condition media (25%). Background was determined with cells
incubated in media from control transfected 293 cells and
subtracted from proliferation seen in sGP-containing
supernatants.
[0016] FIGS. 3A-3C are graphs showing immunization with sGP or GP
expression plasmids induces T cell responses to sGP in guinea
pigs.
[0017] FIGS. 3A-3C. Cell-mediated immunity in guinea pigs was
analyzed by performing assays to detect cell proliferation to
control or GP antigen (A) or T-cell growth factor production in
response to the indicated antigens. The culture supernatants
containing these antigens were prepared as previously described
(Bottomly, K. et al., Measurement of human and murine interleukin 2
and interleukin 4. in Current Protocols in Immunology. (eds.,
Coligan, J. E., Kruisbeek, A. M., Margulies, D. H., Shevach, E. M.
& Strober, W.) 6.3.1-6.3.12 (New York, John Wiley & Sons,
Inc. 1992); Arai, H. et al., Nat. Med. 3:843-848 (1997)), and
included at a final concentration of 10% (volume/volume). In A,
cell numbers refer to the concentration of spleen cells per ml in
the .sup.3H-thymidine proliferation assay. In B, supernatants from
A, harvested at the time of the peak proliferative response to sGP,
were incubated with primary guinea pig T cells maintained in 200
U/ml of human IL-2. The percent maximal response refers to the
magnitude of stimulation in response to the indicated stimuli
relative to supernatants from 24 hour concanaval (in A-stimulated
cells (2 .mu.g/ml)). The requirement of T lymphocytes in guinea pig
spleen cells for the proliferative response to sGP, performed as
described in Specific Example, II. Methods, is shown (C).
[0018] FIGS. 4A-4F are photographs showing the immunohistochemical
analysis of Ebola virus antigens in liver, lung, and spleen from
representative protected (GP-animal 3) or infected (vector-animal
2) guinea pigs.
[0019] FIGS. 4A-4F. Magnification: liver, 40.times.; lung,
20.times.; spleen, 20.times..
[0020] FIG. 5 is a schematic of the plasmid pVR 1012-GP(IC) (Ivory
Coast strain of GP, SEQ ID NO: 1).
[0021] FIG. 6 is a schematic of the plasmid pVR 1012-GP(S) (Sudan
strain of GP, see SEQ ID NO: 2).
[0022] FIG. 7 is a schematic of the plasmid pVR 1012-GP(Z) (Zaire
strain of GP, see SEQ ID NO: 3).
[0023] FIG. 8 is a schematic of the plasmid pVR 1012-sGP(Z) (Zaire
strain of sGP, see SEQ ID NO: 4).
[0024] FIG. 9 is a schematic of the plasmid pVR 1012-NP.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0025] Ebola virus vaccines are provided comprising a nucleic acid
molecule encoding an Ebola viral protein operatively-linked to a
control sequence in a pharmaceutically acceptable carrier. In one
embodiment, the nucleic acid molecule encodes the transmembrane
form of the viral glycoprotein (GP). In another embodiment, the
nucleic acid molecule encodes the secreted form of the viral
glycoprotein (sGP). In yet another embodiment, the nucleic acid
molecule encodes the viral nucleoprotein (NP).
[0026] The present invention further includes vaccines comprising
nucleic acid molecules encoding Ebola viral proteins other than GP,
sGP, and NP, e.g., other structural gene products which elicit
protective immunity from disease caused by infection with Ebola
virus. The nucleic acid molecules of the vaccines of the present
invention encode structural gene products of any Ebola viral strain
including the Zaire, Sudan, Ivory Coast and Reston strains. Nucleic
acid molecules encoding structural gene products of the
genetically-related Marburg virus strains may also be employed.
Moreover, the nucleic acid molecules of the present invention may
be modified, e.g., the nucleic acid molecules set forth herein may
be mutated, as long as the modified expressed protein elicits
protective immunity from disease caused by infection with Ebola
virus. For example, the nucleic acid molecule may be mutated so
that the expressed protein is less toxic to cells. The present
invention also includes vaccines comprising a combination of
nucleic acid molecules. For example, and without limitation,
nucleic acid molecules encoding GP, sGP and NP of the Zaire, Sudan
and Ivory Coast Ebola strains may be combined in any combination,
in one vaccine composition.
[0027] The present invention also provides methods for immunizing a
subject against disease caused by infection with Ebola virus
comprising administering to the subject an immunoeffective amount
of an Ebola virus vaccine. Methods of making and using Ebola virus
vaccines are also provided by the present invention including the
preparation of pharmaceutical compositions.
[0028] As referred to herein, the term "encoding" Is intended to
mean that the subject nucleic acid may be transcribed in a cell,
e.g., when the subject nucleic acid is linked to appropriate
control sequences such as a promoter in a suitable vector (e.g., an
expression vector) and the vector is introduced into a cell. The
nucleic acid molecules of the present invention may be DNA
molecules, cDNA molecules or RNA molecules, and are preferably cDNA
molecules. The term "operatively-linked" as used herein refers to
functional linkage between a nucleic acid expression control
sequence (such as a promoter) and a second nucleic acid sequence,
wherein the expression control sequence directs transcription of
the nucleic acid corresponding to the second sequence. Expression
control sequences are known to those skilled in the art (see, e.g.,
Goeddel, Gene Expression Technology: Methods in Enzymology 185,
Academic Press, San Diego, Calif. (1990)). Vectors which contain
both a promoter and a cloning site to which an inserted piece of
nucleic acid is operatively-linked to the promoter, are well known
in the art and are generally referred to herein as "expression
vectors" or "expression vector plasmids". Preferably, these vectors
are capable of transcribing nucleic acid in vitro and in vivo. A
preferred vector is the cytomegalovirus (CMV) expression vector
which directs high levels of gene expression in muscle.
[0029] Nucleic acid molecules which hybridize under stringent
conditions to the nucleic acid molecules described herein are also
within the scope of the present invention. As will be appreciated
by those skilled in the art, multiple factors are considered in
determining the stringency of hybridization including species of
nucleic acid, length of nucleic acid probe, T.sub.m (melting
temperature), temperature of hybridization and washes, salt
concentration in the hybridization and wash buffers, aqueous or
formamide hybridization buffer, and length of time for
hybridization and for washes. An example of stringent conditions
are DNA-DNA hybridization with a probe greater than 200 nucleotides
in 5.times.SSC, at 65.degree. C. in aqueous solution or 42.degree.
C. in formamide, followed by washing with 0.1.times.SSC, at
65.degree. C. in aqueous solution. (Other experimental conditions
for controlling stringency are described in Maniatis, T. et al.,
Molecular Cloning: a Laboratory Manual, Cold Springs Harbor
Laboratory, Cold Springs, N.Y. (1982) at pages 387-389 and
Sambrook, J. et al., Molecular Cloning: a Laboratory Manual, Second
Edition, Volume 2, Cold Springs Harbor Laboratory, Cold Springs,
N.Y., at pages 8.46-8.47 (1989)).
[0030] It will be appreciated that administration of the vaccines
of the present invention can be by any of the routes normally used
for gene therapy. In a preferred method, administration is by
intramuscular injection, however, other procedures for transfecting
cells may also be employed, such as transfection using calcium
phosphate coprecipitation, liposome-mediated transfection, plasmid
and viral vector-mediated transfection and DNA protein
complex-mediated transfection. Viral vector-mediated transfection
includes, without limitation, the use of retroviral,
replication-deficient retroviral, adenoviral and adeno-associated
viral vectors. Cells transfected by the vaccines in the context of
ex vivo gene therapy can also be administered.
[0031] It will be appreciated that more than one route of
administering the vaccines of the present invention may be employed
either simultaneously or sequentially (e.g., boosting). In
addition, the vaccines of the present invention may be employed in
combination with traditional immunization approaches such as
employing protein antigens, vaccinia virus and inactivated virus,
as vaccines. Thus, in one embodiment, the vaccines of the present
invention are administered to a subject (the subject is "primed"
with a vaccine of the present invention) and then a traditional
vaccine is administered (the subject is "boosted" with a
traditional vaccine). In another embodiment, a traditional vaccine
is first administered to the subject followed by administration of
a vaccine of the present invention. In yet another embodiment, a
traditional vaccine and a vaccine of the present invention are
co-administered.
[0032] Immunogenicity may be significantly improved if the vaccines
of the present invention are co-administered with an
immunostimulatory agent or adjuvant. Adjuvants enhance
immunogenicity but are not necessarily immunogenic themselves.
Immunostimulatory agents or adjuvants have been used for many years
to improve the host immune responses to, for example, vaccines.
Adjuvants may thus be employed to enhance the immunogenicity of the
vaccines of the present invention, as well as the immunogenicity of
traditional vaccines. Suitable adjuvants are well known to those
skilled in the art and include, without limitation, aluminum
phosphate, aluminum hydroxide, QS21, Quil A, derivatives and
components thereof, calcium phosphate, calcium hydroxide, zinc
hydroxide, a glycolipid analog, an octodecyl ester of an amino
acid, a muramyl dipeptide, polyphosphazene, a lipoprotein, ISCOM
matrix, DC-Chol, DDA, and other adjuvants and bacterial toxins,
components and derivatives thereof.
[0033] The vaccines of the present invention may also be
co-administered with cytokines to further enhance immunogenicity.
The cytokines may be administered by methods known to those skilled
in the art, e.g., as a nucleic acid molecule in plasmid form or as
a protein or fusion protein.
[0034] Upon inoculation with a pharmaceutical composition as
described herein, the immune system of the host responds to the
vaccine by producing antibodies, both secretory and serum, specific
for Ebola virus proteins. As a result of the vaccination, the host
becomes at least partially or completely immune to Ebola virus
infection, or resistant to developing moderate or severe disease
caused by Ebola virus infection. Although Ebola virus infection and
disease caused thereby are discussed in detail herein, it will be
appreciated that the vaccines and methods of the present invention
may be employed to immunize a subject against hemorrhagic fever
generally, such as that caused by infection by the
genetically-related Marburg virus.
[0035] Pharmaceutical compositions comprising the nucleic acid
molecules encoding Ebola viral proteins described herein, either
alone or in combination, and a pharmaceutically acceptable carrier,
are also provided by the present invention. As used herein, the
phrase "pharmaceutically acceptable carrier" encompasses any of the
standard pharmaceutical carriers, such as those suitable for
parenteral administration, such as, for example, by intramuscular,
intraarticular (in the joints), intravenous, intradermal,
intraperitoneal, and subcutaneous routes. Examples of such
formulations include aqueous and non-aqueous, isotonic sterile
injection solutions, which contain antioxidants, buffers,
bacteriostats, and solutes that render the formulation isotonic
with the blood of the intended recipient, and aqueous and
non-aqueous sterile suspensions that can include suspending agents,
solubilizers, thickening agents, stabilizers, and
preservatives.
[0036] Formulations suitable for oral administration can consist of
(a) liquid solutions, such as an effective amount of the vaccine
dissolved in diluents, such as water, saline or PEG 400; (b)
capsules, sachets or tablets, each containing a predetermined
amount of the vaccine, as liquids, solids, granules or gelatin; (c)
suspensions in an appropriate liquid; (d) suitable emulsions; and
(e) polysaccharide polymers such as chitians. The vaccine, alone or
in combination with other suitable components, may also be made
into aerosol formulations to be administered via inhalation, e.g.,
to the bronchial passageways. Aerosol formulations can be placed
into pressurized acceptable propellants, such as
dichlorodifluoromethane, propane, nitrogen, and the like.
[0037] Suitable formulations for rectal administration include, for
example, suppositories, which consist of the vaccine with a
suppository base. Suitable suppository bases include natural or
synthetic triglycerides or paraffin hydrocarbons. In addition, it
is also possible to use gelatin rectal capsules which consist of a
combination of the vaccine with a base, including, for example,
liquid triglycerides, polyethylene glycols, and paraffin
hydrocarbons.
[0038] Each carrier must be "acceptable" in the sense of being
compatible with the other ingredients of the formulation and not
injurious to the recipient, e.g., the patient. The formulations can
be presented in unit-dose or multi-dose sealed containers, such as
ampules or vials and may be prepared by any method known in the
art.
[0039] Pharmaceutical compositions comprising any of the nucleic
acid molecules encoding Ebola viral proteins of the present
invention are useful to immunize a subject against disease caused
by Ebola virus infection. Thus, this invention further provides
methods of immunizing a subject against disease caused by Ebola
virus infection, e.g., hemorrhagic fever, comprising administering
to the subject an immunoeffective amount of a pharmaceutical
composition of the invention. This subject may be an animal, for
example a mammal, such as a primate or preferably a human.
[0040] The vaccines of the present invention are also suitable for
veterinary immunization. The vaccines of the present invention
comprising nucleic acid molecules encoding Ebola virus structural
gene products from the Reston strain, which is known to infect
animals, are particularly useful in such veterinary immunization
methods.
[0041] The vaccines are administered in a manner compatible with
the dosage formulation, and in such amount as will be
therapeutically effective, immunogenic and protective. The quantity
to be administered depends on the subject to be treated, including,
for example, the capacity of the immune system of the individual to
synthesize antibodies, and, if needed, to produce a cell-mediated
immune response. Precise amounts of active ingredient required to
be administered depend on the judgment of the practitioner and may
be monitored on a patient-by-patient basis. However, suitable
dosage ranges are readily determinable by one skilled in the art
and generally range from about 300 .mu.g to about 4-5 mg. The
dosage may also depend, without limitation, on the route of
administration, the patient's state of health and weight, and the
nature of the formulation.
[0042] Methods of immunizing a subject against multiple strains of
Ebola virus are further provided herein. The nucleic acid molecules
encoding Ebola viral proteins of the present invention may be
combined with nucleic acid molecules encoding other viral proteins
of other virus strains to achieve protection against multiple
strains of Ebola virus. Typically the vaccines will be in an
admixture and administered simultaneously, but may also be
administered separately.
[0043] In some instances it may be desirable to combine the Ebola
virus vaccines of the present invention with vaccines which induce
protective responses to other agents, particularly other viruses.
For example, the vaccine compositions of the present invention can
be administered simultaneously, separately or sequentially with
other genetic immunization vaccines such as those for influenza
(Ulmer, J. B. et al., Science 259:1745-1749 (1993); Raz, E. et al.,
PNAS (USA) 91:9519-9523 (1994)), malaria (Doolan, D. L. et al., J.
Exp. Med. 183:1739-1746 (1996); Sedegah, M. et al., PNAS (USA)
91:9866-9870 (1994)), and tuberculosis (Tascon, R. C. et al., Nat.
Med. 2:888-892 (1996)).
[0044] It will also be appreciated that single or multiple
administrations of the vaccine compositions of the present
invention may be carried out. For example, subjects who are
particularly susceptible to Ebola virus infection may require
multiple immunizations to establish and/or maintain protective
immune responses. Levels of induced immunity can be monitored by
measuring amounts of neutralizing secretory and serum antibodies,
and dosages adjusted or vaccinations repeated as necessary to
maintain desired levels of protection.
[0045] This invention also provides kits comprising the vaccines of
the present invention. For example, kits comprising a vaccine and
instructions for use are within the scope of this invention.
[0046] The vaccines and methods of the present invention evoke a
protective immune response and do not lead to immunopotentiation or
exacerbated disease. The vaccines lack transmissibility, are
genetically stable and induce protective levels of humoral and
cell-mediated immunity.
[0047] In order to more fully demonstrate the advantages arising
from the present invention, the following example is set forth. It
is to be understood that the following is by way of example only
and is not intended as a limitation on the scope of the
invention.
SPECIFIC EXAMPLE
[0048] I. Results
[0049] Immune response to viral gene products in mice. To
characterize immune responses to selected Ebola virus proteins,
eukaryotic expression vector plasmids were injected into mice. The
cytomegalovirus (CMV) immediate early region 1 enhancer was used to
stimulate transcription because ft directs high levels of gene
expression in muscle. Manthorpe, M. et al., Hum. Gene. Ther.
4:419-431 (1993). cDNAs encoding an abundant structural protein,
the major viral nucleocapsid phosphoprotein (NP), the secreted
glycoprotein (sGP), or the membrane-associated glycoprotein (GP)
were inserted. Alternative forms of GP were chosen because it had
been postulated that the transmembrane protein contained a protein
sequence motif also found in oncogenic retroviruses that might
suppress immune responses. Burkreyev, A. A. et al., FEBS. Lett.
323:183-187 (1993); Cianciolo, G. J. et al., Science 230:453-455
(1985); Harris, D. T. et al., J. Immunol. 138:889-894 (1987);
Volchkov, V. E. et al., FEBS. Lett. 305:181-184 (1992); Sanchez, A.
et al., Virus. Res. 29:215-240 (1993). Expression of the relevant
proteins was confirmed after transfection of the human renal
epithelial cell line, 293, by immunoblotting with antisera to these
gene products (FIG. 1A). For NP, the expected full-length 104 kDa
protein normally produced by the virus was seen, together with
lower molecular weight species likely generated from truncated
protein or degradation products described previously. Sanchez, A.
et al., Virology 170:81-91 (1989). Similarly, expression of sGP and
GP revealed a heterogeneous pattern whose sizes correlated with the
expected products of cleavage or post-translational carbohydrate
modification. Sanchez, A. et al., PNAS (USA) 93:3602-3607
(1996).
[0050] These plasmids were injected into mice to characterize their
ability to induce humoral and cellular immune responses to the
relevant viral proteins. Three injections, each with 50 .mu.g of
plasmid DNA in saline (100 .mu.l), were performed at two-week
intervals in Balb/C female mice (6-8 week old, Charles River).
Serum from immunized recipients were examined for antibody
responses. An antibody response to the viral NP gene product was
readily detectable (FIG. 1B), with titers of .gtoreq.1:16,000 by
Western blot analysis. The titer of antibody induced in response to
injection with plasmids encoding the viral glycoproteins was lower.
After immunization with GP, no antibody was detectable by Western
blotting, while immunization with sGP induced an antibody response
(FIG. 1B). The more sensitive ELISA (Ksiazek, T. G., Lab. Anim.
20:34-46 (1991); Ksiazek, T. G. et al., J. Clin. Microbiol.
30:947-950 (1992)) did allow detection of antibodies to both GP and
sGP at titers of 1:400 and 1:1,200, respectively. Cytolytic T cell
(CTL) responses to these viral proteins were analyzed next. Despite
the substantial humoral immune response to NP, minimal CTL activity
was detected against syngeneic cells expressing this viral protein
(FIG. 2A). In contrast, genetic immunization with sGP, which
elicited a weaker antibody response, induced a marked cytolytic T
cell response to cells expressing GP (FIG. 2B). Immunization with
the GP plasmid also induced a significant CTL response to GP (FIG.
2C). These data suggested that both the secreted and transmembrane
form of the protein could be processed for antigen presentation and
the transmembrane form was a target for recognition by these
cytolytic T cells. Finally, antigen-specific T cell proliferation
to sGP was also observed in GP and sGP but not plasmid control
injected mice (FIG. 2D).
[0051] The ability of antibodies detected in mouse sera after
immunization to neutralize virus was tested in an in vitro
infection assay. McCormick, J. B. et al., J. Infect. Dis.
147:264-267 (1983). In no case was neutralization of infectivity
observed, even at titers of 1:10 (data not shown), despite the
documented presence of antibody after NP and sGP immunization by
Western blot analysis. Infectivity in vitro was thus not inhibited
by Ebola-specific antibodies.
[0052] Immune function and viral challenge in guinea pigs. To
determine whether the in vivo immune responses could protect
against viral infection, virus was adapted to growing guinea pigs.
Though this species is not well-suited to analysis of immune
function, infection in adult mice has not been successful.
Moreover, infection in guinea pigs, used originally to propagate
virus from infected humans, is a well-established animal model for
the human disease. Infection gives rise to a syndrome of
hemorrhagic fever with levels of virus, organ pathology, and
infection of reticuloendothelial and mononudear cells comparable to
humans. Bowen, E. T. W. et al., Lancet 1:571-573 (1977).
[0053] Two groups of immunized guinea pigs were studied. Animals
were injected intramuscularly with the relevant expression vector
plasmids, and the response to infection in groups immunized with
either sGP, GP, NP, or control plasmids was observed. In the first
group, animals were challenged within 2 months after the initial
immunization, at which time the antibody titers were high, ranging
from 1:1,600 to >1:25,000 (Table 1A). In these animals, nearly
complete protection from lethal challenge was observed in GP (6/6),
sGP (5/6), and NP (4/4) immunized subjects, in contrast to controls
(0/6). In a second group, guinea pigs were challenged four months
after the initial immunization (Table 1B). As in the first group,
all animals immunized with the control vector succumbed to
infection within a week after virus challenge (n=4). In this group,
antibody titers were lower, and three of the four guinea pigs
immunized with NP succumbed to infection, with the single survivor
appearing severely ill after 1 week, in contrast to the protective
response with NP at the earlier time point after immunization in
Group I. More effective protection was seen in animals immunized
with vector expressing GP, protection was noted in four of five
animals challenged, with one survivor appearing weak but surviving
the viral challenge. Similarly, three of the five animals immunized
with sGP showed no ill effects following viral challenge.
Protection in this group again correlated with the ability to
sustain an effective immune response to GP or sGP. Together, all
guinea pigs immunized with vectors expressing GP or sGP which had
titers greater than 1:5,120 were resistant to infection (11/11)
compared to 0/10 controls (p=0, by Fisher's exact test). Twelve of
fourteen animals with antibody titers .gtoreq.2,560 survived viral
challenge compared to controls (p=0.00003, by Fisher's exact test).
Similar to immunized mice, guinea pigs injected with GP or sGP
plasmids were able to generate cell-mediated immune responses to
the viral glycoprotein in addition to the antibody response. These
responses were antigen-specific and T cell-dependent, as detected
in sGP antigen-dependent spleen cell proliferation and T-cell
growth factor assays (FIG. 3A-C). Thus, the ability to generate and
sustain significant cellular immune responses in vivo correlated
with protection from infection. Though antibody titer correlated
with protection, cell-mediated immunity appeared necessary for
protection since passive transfer of antibody to GP does not confer
protection (Peters, C. J. et al., Filovirdae: Marburg and Ebola
Viruses. in Fields Virology. (eds., Fields, B. N., Knipe, D. M.
& Howley, P. M.) 1161-1176 (Philadelphia, Lippincott-Raven,
1996); Jahrling, P. B. et al., Arch. Virol. Suppl. 11:135-140
(1996)) and antisera from protected guinea pigs did not inhibit
virus replication in vivo (n=3) or at a 1:10 dilution in vitro
(data not shown). Since the Hartley guinea pig to which the virus
has been adapted for growth is outbred, cellular adoptive transfer
studies could not be performed.
1TABLE 1 Group I Plasmid Subject ELISA(Pre) ELISA(Post) Viral Ag
Survival GP 1 >1:25,600 1:12,800 - Yes GP 2 >1:25,600
1:25,600 - Yes GP 3 >1:25,600 1:25,600 - Yes GP 4 1:25,600
1:6,400 - Yes GP 5 1:25,600 1:12,800 - Yes GP 6 1:25,600 1:25,600 -
Yes SGP 1 1:12,800 1:25,600 - Yes SGP 2 1:6,400 1:25,600 - Yes SGP
3 1:6,400 1:25,600 - Yes SGP 4 1:25,600 1:25,600 - Yes SGP 5
>1:25,600 1:12,800 - Yes SGP 6 1:1,600 Negative + No NP 1
1:12,800 >1:25,600 - Yes NP 2 >1:25,600 1:25,600 - Yes NP 3
1:12,800 1:12,800 - Yes NP 4 1:25,600 1:25,600 - Yes Vector alone 1
Negative Negative + No Vector alone 2 Negative n.d. + No Vector
alone 3 Negative Negative + No Vector alone 4 Negative Negative +
No Vector alone 5 Negative n.d. + No Vector alone 6 Negative n.d. +
No Guinea pigs were immunized on days 1, 14, 28, 42, and challenged
on day 62.
[0054]
2TABLE 1 Group II Plasmid Subject ELISA(Pre) ELISA(Post) Viral Ag
Survival GP 1 1:2,560 n.d. +/f No GP 2 1:5,120 1:10,240 - Yes GP 3
1:10,240 1:10,240 - Yes GP 4 1:1,280 n.d. +/f No GP 5 1:5,120
1:20,480 - Yes (ill) SGP 1 1:2,560 n.d. + No SGP 2 1:10,240 1:5,120
+/f Yes SGP 3 1:10,240 1:81,920 - Yes SGP 4 1:2,560 1:5,120 - Yes
SGP 5 1:640 n.d. + No NP 1 n.d. n.d. + No NP 2 n.d. n.d. + No NP 3
n.d. n.d. + No NP 4 n.d. Negative + Yes (ill) Vector alone 1
Negative n.d. + No Vector alone 2 Negative n.d. + No Vector alone 3
Negative n.d. + No Vector alone 4 Negative n.d. + No Guinea pigs
were immunized on days 1, 14, 42, and 112 and challenged on day
122. n.d. = not done. Viral ag denotes presence of virus determined
by immunohistochemistry (30) performed on spleen, liver, lung,
kidney, and heart tissues; "+" = widespread systemic involvement of
the mononuclear phagocyte system and to a lesser extent endothelial
and parenchymal cells; "+/f" = focal involvement (seen in the
spleen of SGP #2, the liver and spleen of GP #1, and the lung of
GP#4) where rare sites of anti-Ebola antibody staining were
detected.; "-" = no Ebola virus antigen detected in tissues. ELISA
determinations made prior to viral challenge (Pre) or at least 7
days after (Post) infection, respectively. The surviving NP
immunized animal (4) was found to have significant levels of virus
in major organs by immunohistochemistry, and more than 5 logs of
virus was detected in the serum and spleen, in contrast to GP and
sGP animals where no virus was detected.
[0055] Histopathologic analysis of infection in immunized guinea
pigs. Pathologic analysis revealed widespread tissue necrosis and
dissemination of virus by immunohistochemistry, similar to human
disease. Virus load correlated with susceptibility to infection
with titers of .gtoreq.10.sup.5 in infected animals compared to
undetectable levels in immunized survivors. In infected animals,
the liver, lung, and spleen showed evidence of significant viral
antigen by immunohistochemistry (FIG. 4, Table 1), and both
reticuloendothelial and mononuclear phagotic involvement was
observed.
[0056] Determination of antibody response in animals which survived
virus challenge revealed increases in the immune response to viral
proteins when initial titers were lower (Table 1). Less consistent
increases in antibody titers were observed in the NP immunized
animals. These data suggest that Ebola virus infection may
stimulate immunity in survivors of a viral challenge when immune
responses are not optimal.
[0057] II. Methods
[0058] Plasmids. Plasmids containing the GP, sGP, or NP cDNAs
(Sanchez, A. et al., Virus. Res. 29:215-240 (1993), Genbank) were
used to subclone the relevant inserts into CMV expression vectors
which utilized the bovine growth hormone polyadenylation sequence.
Manthorpe, M. et al., Hum. Gene. Ther. 4:419-431 (1993). (see FIGS.
5-9 and SEQ ID NOS: 1-4). Briefly, for GP, plasmid pGEM-3Zf(-)-GP
was digested with EcoR I, treated with the Klenow fragment of E.
coli DNA polymerase, and digested with BamH I. The GP fragment was
then inserted into the pCMV expression vector plasmid digested with
BamH I, Klenow fragment and Bgl II. For sGP, the plasmid pCRII-sGP
was digested with EcoR I, treated with Klenow enzyme, and the
resulting fragment inserted into the BamH I/Bgl II CMV plasmid
which had been incubated with Klenow fragment, calf intestinal
phosphatase (CIP), then phenol chloroform extract. For the NP
expression vector, plasmid pSP64-NP2 (Sanchez, A. et al., Virology
170:81-91 (1989)) was digested with EcoR I, treated with Klenow
enzyme, and digested with BamH I. The NP insert was cloned into CMV
treated with BamH I, Klenow enzyme, followed by heat inactivation
and Bgl II digestion.
[0059] Cell lines and transfectants. For stable transfectants, the
relevant cDNAs were inserted into a CMV expression plasmid
containing a neomycin resistant gene, pCMV-neo (H. Arai,
unpublished data), which was digested with Xba I, and treated with
CIP and Klenow enzyme. The EcoR I/BamH I GP fragment from
pGEM-3Zf(-)-GP, the EcoR I sGP fragment from pCRII-SGP, or the EcoR
I/BamH I NP fragment from pSP64-NP2 was treated with Klenow enzyme
and ligated to this plasmid backbone. These vectors were
transfected into Renca or CT26 which was syngeneic to Balb/C mice
using calcium phosphate and selected in 0.7 or 1 mg/ml G418 for 2-6
weeks. Expression of GP, sGP, or NP from these vectors in Renca or
CT26 cells was also confirmed by Western blot analysis (data not
shown).
[0060] Cell proliferation assay. Spleen cells from male Hartley
guinea pigs or Balb/C female mice (8-10 weeks) immunized with the
indicated plasmid expression vectors were incubated with sGP or
vector control supernatants (25% volume:volume) from transfected
293 cells at the indicated cell concentrations. T cell depletion
was performed using the CT5 monoclonal antibody (Tan, B. T. G. et
al., Hybridoma 4:115-124 (1985)) (Biosource, Camarillo, Calif.) for
guinea pigs or anti-Thy 1.2 antibody in the mouse using
immunomagnetic microbeads (Miltenyl Biotec, Inc., Auburn,
Calif.).
[0061] Viral challenge in guinea pigs. Animals were immunized by
injection of 100 .mu.l (0.5 mg/ml) in each hind leg (two injections
at each time point) with the indicated plasmid expression vectors.
Animals were challenged by inoculation with a stock of Ebola virus
(Zaire, 1976) that had been passaged once in vero E6 cells and
serially passaged by intraperitoneal injection of spleen
homogenates in Hartley guinea pigs seven times. Immunized guinea
pigs were injected intraperitoneally with 0.5 ml of a 1:1,000
dilution of spleen cell homogenate in Hank's balanced salt solution
122 days after the initial plasmid DNA injection (1000 pfu).
Survival was determined 10 days later at which times animals were
sacrificed for serologic and pathologic analysis. ELISA,
enzyme-linked immunosorbent assay (Volchkov, V. E. et al., FEBS.
Lett. 305:181-184 (1992); Sanchez, A. et al., Virus. Res.
29:215-240 (1993)) on infected cell supernatants and enriched viral
extracts containing GP, sGP, or NP were performed as previously
described.
[0062] III. Discussion
[0063] Following the initial report that injection of plasmid DNA
into muscle could direct the synthesis of recombinant proteins
(Wolff, J. A. et al., Science 247:1465-1468 (1990)), the suggestion
was made that this gene transfer approach may be useful for
vaccination and was termed genetic immunization. Tang, D. C. et
al., Nature 356:152-154 (1992). This approach has been applied to
different infectious diseases, including influenza (Ulmer, J. B. et
al., Science 259:1745-1749 (1993); Raz, E. et al., PNAS (USA)
91:9519-9523 (1994)), malaria (Doolan, D. L. et al., J. Exp. Med.
183:1739-1746 (1996); Sedegah, M. et al., PNAS(USA) 91:9866-9870
(1994)), and tuberculosis (Tascon, R. C. et al., Nat Med. 2:888-892
(1996)) and has also been used to modulate antibody and
cell-mediated immune responses in autoimmune and allergic diseases.
Raz, E. et al., PNAS (USA) 90:4523-4527 (1993); Waisman, A. et al.,
Nat. Med. 2:899-905 (1996); McCormick, J. B. et al., J. Infect.
Dis. 147:264-267 (1983); Border, W. A. et al., Nat. Med.
1:1000-1001 (1995).
[0064] The immune response to selected Ebola virus proteins after
genetic immunization in mice was analyzed and their ability to
protect against lethal infection in a susceptible animal model, the
guinea pig, was tested. The immune analyses performed in different
species suggest similar patterns of response, though the specific
peptides which may be recognized by the immune system to confer
protection in the guinea pig could differ from the mouse. Because
the principles of MHC antigen presentation and recognition apply
broadly across species (Monaco, J. J., Immunol. Today 13:173-179
(1992); Jorgensen, J. L. et al., Annu. Rev. Immunol. 10:835-873
(1992); Zinkemagel, R. M. et al., Immunol. Today 18:14-17 (1997)),
the finding that protection was observed in different members of an
outbred strain and that similar immune responses were seen in
different species is not unexpected and suggests that this approach
may be applicable to humans.
[0065] Immunization with plasmids encoding distinct viral proteins
induced different antibody and cytolytic T cell responses. The
broadest immune response was conferred by GP and sGP, which induced
both cellular and humoral immunity to the membrane-associated GP.
In guinea pigs challenged with doses of virus that are otherwise
lethal, sGP provided nearly equivalent protection to GP, with no
significant difference between these groups. The ability of vectors
expressing GP to confer immunity may be explained by the generation
of lower molecular weight degradation products (FIG. 1B) which
could provide sufficient protein for antigen presentation to induce
detectable, cellular, and humoral immune responses in guinea
pigs.
[0066] Despite the fact that plasmid DNA injection has been shown
to affect the immune response to different antigens in infectious
and autoimmune diseases, the ability of individual gene products to
protect against disease in vivo is not readily predictable. In
particular, the rapid rates of Ebola virus replication and the poor
immunogenicity of its proteins had previously rendered it resistant
to immune interventions. Several attempts to confer protection with
passive transfer of immunoglobulin were unsuccessful (Peters, C. J.
et al., Filoviridae: Marburg and Ebola Viruses. in Fields Virology.
(eds., Fields, B. N., Knipe, D. M. & Howley, P. M.) 1161-1176
(Philadelphia, Lippincott-Raven, 1996); Jahrling, P. B. et al.,
Arch. Virol. Suppl. 11:135-140 (1996)), in agreement with the
finding set forth herein that antisera from protected animals fails
to neutralize virus replication in vitro. Previous studies using
formalin-fixed virus or purified viral proteins for immunization
have also not proven effective. Peters, C. J. et al., Filoviridae:
Marburg and Ebola Viruses. in Fields Virology. (eds., Fields, B.
N., Knipe, D. M. & Howley, P. M.) 1161-1176 (Philadelphia,
Lippincott-Raven, 1996); Clegg, J. C. S. & Sanchez, A. Vaccines
against arenaviruses and filoviruses. In New Generation Vaccines.
(eds., Levine, M. M., Woodrow, G. C., Kaper, J. B. & Cobon, G.
S.) 749-765 (New York, N.Y., Marcel Dekker, Inc. 1997).
[0067] It is likely that traditional immunization approaches using
protein antigens, vaccinia virus, or inactivated virus do not allow
for appropriate uptake and presentation of viral antigens by
dendritic or other antigen-presenting cells to induce protective
immune responses. It has been shown recently that genetic
immunization leads to production of recombinant protein(s) in
muscle which are delivered to bone marrow-derived
antigen-presenting cells. Iwasaki, A. et al., J. Immunol. 159:11-14
(1997); Doe, B. et al., PNAS (USA) 93:8578-8583 (1996); Corr, M. et
al., J. Exp. Med. 184:1555-1560 (1996). Synthesis of Ebola
glycoprotein after gene transfer apparently allows more efficient
processing and presentation and the generation of immune responses
not seen with virus or with viral vectors. GP is a large molecule
which contains both T and B cell epitopes. Although antibody levels
provide a surrogate marker of protection, the fact that passive
transfer of antibody did not confer protection implies that
immunoglobulin switching and synthesis is reflective of the T
helper response to GP. Genetic immunization stimulates T helper
cells to generate both CTL and B cell antibody responses to the
virus. Although antibody production confirms effective
immunization, a productive T cell response, likely involving
T.sub.H1 cell stimulation, as shown by the T cell proliferation and
CTL assays (FIG. 3), is needed for effective immunity. Taken
together, these studies suggest that transcription and translation
of viral genes in host cells by genetic immunization induces
alternative, more effective, processing and antigen presentation
which better stimulates immunity to Ebola virus. Since there are
yet no effective antiviral agents, the ability to generate
protective immunity by vaccination may prove useful in selected
high risk populations, particularly in regions of ongoing
outbreaks, and among medical and laboratory personnel exposed to
the virus. Although it remains important to identify agents which
treat acute infection, genetic immunization may help to limit the
spread of this highly lethal infectious disease.
[0068] The foregoing discussion discloses and describes merely
exemplary embodiments of the present invention. One skilled in the
art will readily recognize from such discussion, and from the
accompanying drawings and claims, that various changes,
modifications and variations can be made therein without departing
from the spirit and scope of the invention as defined in the
following claims.
[0069] All references cited herein are incorporated by reference as
if fully set forth.
Sequence CWU 1
1
4 1 7003 DNA Artificial Sequence Description of Artificial
SequencePlasmid containing DNA forGP of Ebola Virus, Ivory Coast
strain 1 tcgcgcgttt cggtgatgac ggtgaaaacc tctgacacat gcagctcccg
gagacggtca 60 cagcttgtct gtaagcggat gccgggagca gacaagcccg
tcagggcgcg tcagcgggtg 120 ttggcgggtg tcggggctgg cttaactatg
cggcatcaga gcagattgta ctgagagtgc 180 accatatgcg gtgtgaaata
ccgcacagat gcgtaaggag aaaataccgc atcagattgg 240 ctattggcca
ttgcatacgt tgtatccata tcataatatg tacatttata ttggctcatg 300
tccaacatta ccgccatgtt gacattgatt attgactagt tattaatagt aatcaattac
360 ggggtcatta gttcatagcc catatatgga gttccgcgtt acataactta
cggtaaatgg 420 cccgcctggc tgaccgccca acgacccccg cccattgacg
tcaataatga cgtatgttcc 480 catagtaacg ccaataggga ctttccattg
acgtcaatgg gtggagtatt tacggtaaac 540 tgcccacttg gcagtacatc
aagtgtatca tatgccaagt acgcccccta ttgacgtcaa 600 tgacggtaaa
tggcccgcct ggcattatgc ccagtacatg accttatggg actttcctac 660
ttggcagtac atctacgtat tagtcatcgc tattaccatg gtgatgcggt tttggcagta
720 catcaatggg cgtggatagc ggtttgactc acggggattt ccaagtctcc
accccattga 780 cgtcaatggg agtttgtttt ggcaccaaaa tcaacgggac
tttccaaaat gtcgtaacaa 840 ctccgcccca ttgacgcaaa tgggcggtag
gcgtgtacgg tgggaggtct atataagcag 900 agctcgttta gtgaaccgtc
agatcgcctg gagacgccat ccacgctgtt ttgacctcca 960 tagaagacac
cgggaccgat ccagcctccg cggccgggaa cggtgcattg gaacgcggat 1020
tccccgtgcc aagagtgacg taagtaccgc ctatagactc tataggcaca cccctttggc
1080 tcttatgcat gctatactgt ttttggcttg gggcctatac acccccgctt
ccttatgcta 1140 taggtgatgg tatagcttag cctataggtg tgggttattg
accattattg accactcccc 1200 tattggtgac gatactttcc attactaatc
cataacatgg ctctttgcca caactatctc 1260 tattggctat atgccaatac
tctgtccttc agagactgac acggactctg tatttttaca 1320 ggatggggtc
ccatttatta tttacaaatt cacatataca acaacgccgt cccccgtgcc 1380
cgcagttttt attaaacata gcgtgggatc tccacgcgaa tctcgggtac gtgttccgga
1440 catgggctct tctccggtag cggcggagct tccacatccg agccctggtc
ccatgcctcc 1500 agcggctcat ggtcgctcgg cagctccttg ctcctaacag
tggaggccag acttaggcac 1560 agcacaatgc ccaccaccac cagtgtgccg
cacaaggccg tggcggtagg gtatgtgtct 1620 gaaaatgagc gtggagattg
ggctcgcacg gctgacgcag atggaagact taaggcagcg 1680 gcagaagaag
atgcaggcag ctgagttgtt gtattctgat aagagtcaga ggtaactccc 1740
gttgcggtgc tgttaacggt ggagggcagt gtagtctgag cagtactcgt tgctgccgcg
1800 cgcgccacca gacataatag ctgacagact aacagactgt tcctttccat
gggtcttttc 1860 tgcagtcacc gtcgtcgaca cgtgtgatca gatatcgcgg
ccgcgcggcc gctctagaat 1920 tctctaatca cagtcatcat gggagcgtca
gggattctgc aattgccccg tgagcgcttc 1980 aggaaaacat ctttctttgt
ttgggtaata atcctattcc ataaagtctt ttcaatcccg 2040 ttgggggttg
tacacaacaa taccctacaa gtgagtgata ttgacaagtt tgtgtgccga 2100
gacaaactct cttcaactag ccaattgaag tcagtcgggt tgaacttgga gggcaatgga
2160 gtagcaactg atgtaccaac ggcaaccaaa agatggggtt ttcgagctgg
tgttccacca 2220 aaggtggtaa attacgaagc tggagaatgg gctgagaact
gttataacct ggctataaag 2280 aaagttgatg gtagtgagtg cctaccagaa
gcccctgagg gagtgaggga ttttccccgt 2340 tgccgctatg tacacaaagt
ctcaggaact ggaccatgcc caggaggact cgcctttcac 2400 aaagaaggag
ccttcttcct gtatgaccga ctcgcatcaa caatcattta tcggggtaca 2460
acctttgccg aaggagttat tgcatttctg atcttgccta aggcgcgaaa ggattttttc
2520 cagtctcctc cattgcatga gcctgccaac atgaccacgg atccctccag
ttactatcac 2580 acgacaacaa taaactacgt ggttgataat tttggaacca
acaccacaga gtttctgttc 2640 caagtcgatc atttgacgta tgtgcagctc
gaggcaagat tcacaccaca attccttgtc 2700 ctcctaaatg aaaccatcta
ctctgataac cgcagaagta acacaacagg aaaactaatc 2760 tggaaaataa
atcccactgt tgataccagc atgggtgagt gggctttctg ggaaaataaa 2820
aaaacttcac aaaaaccctt tcaagtgaag agttgtcttt cgtacctgta ccagaaaccc
2880 agaaccaggt ccttgacacg acagcgacgg tctctcctcc catctccgcc
cacaaccacg 2940 caggcgaaga ccacaaagaa ttggtttcag aggattccac
tccagtggtt cagatgcaaa 3000 acatcaaggg aaaggacaca atgccaacca
cagtgacggg tgtaccaaca accacaccct 3060 ctccatttcc aatcaatgct
cgcaacactg atcataccaa atcatttatc ggcctggagg 3120 ggccccaaga
agaccacagc accacacagc ctgccaagac caccagccaa ccaaccaaca 3180
gcacagaatc gacgacacta aacccaacat cagagccctc cagtagaggc acgggaccat
3240 ccagccccac ggtccccaac accacagaaa gccacgccga acttggcaag
acaaccccaa 3300 ccacactccc agaacagcac actgccgcca gtgccattcc
aagagccgtg caccccgacg 3360 aactcagtgg acctggcttc ctgacgaaca
caatacgggg ggtgacaaat ctcctgacag 3420 gatccagaag aaagcgaagg
gatgtcactc ccaatacaca acccaaatgc aacccaaacc 3480 tgcactattg
gacagccttg gatgagggtg ctgccatagg tttagcctgg ataccatact 3540
tcgggccagc agctgaggga atttacactg aaggcataat ggagaatcaa aatggattga
3600 tctgtggatt gaggcagctg gccaacgaaa cgacacaagc tcttcaattg
ttcttaaggg 3660 caactactga gttgcgtaca ttctctatac taaatcggaa
agcaatagac ttcttgctcc 3720 aaagatgggg aggaacatgt cacattctag
ggcctgattg ttgcattgaa ccccaagatt 3780 ggaccaaaaa tatcactgat
aaaattgatc aaataatcca tgactttgtc gataataatc 3840 ttccaaatca
gaatgatggc agcaactggt ggactggatg gaaacaatgg gttcctgctg 3900
gaataggaat cacaggagta atcattgcta ttattgcttt gctgtgcatt tgcaaattca
3960 tgctttgaac taatatagca tcatacttta gaattctaga ccaggcgcct
ggatccagat 4020 ctgctgtgcc ttctagttgc cagccatctg ttgtttgccc
ctcccccgtg ccttccttga 4080 ccctggaagg tgccactccc actgtccttt
cctaataaaa tgaggaaatt gcatcgcatt 4140 gtctgagtag gtgtcattct
attctggggg gtggggtggg gcagcacagc aagggggagg 4200 attgggaaga
caatagcagg catgctgggg atgcggtggg ctctatgggt acccaggtgc 4260
tgaagaattg acccggttcc tcctgggcca gaaagaagca ggcacatccc cttctctgtg
4320 acacaccctg tccacgcccc tggttcttag ttccagcccc actcatagga
cactcatagc 4380 tcaggagggc tccgccttca atcccacccg ctaaagtact
tggagcggtc tctccctccc 4440 tcatcagccc accaaaccaa acctagcctc
caagagtggg aagaaattaa agcaagatag 4500 gctattaagt gcagagggag
agaaaatgcc tccaacatgt gaggaagtaa tgagagaaat 4560 catagaattt
cttccgcttc ctcgctcact gactcgctgc gctcggtcgt tcggctgcgg 4620
cgagcggtat cagctcactc aaaggcggta atacggttat ccacagaatc aggggataac
4680 gcaggaaaga acatgtgagc aaaaggccag caaaaggcca ggaaccgtaa
aaaggccgcg 4740 ttgctggcgt ttttccatag gctccgcccc cctgacgagc
atcacaaaaa tcgacgctca 4800 agtcagaggt ggcgaaaccc gacaggacta
taaagatacc aggcgtttcc ccctggaagc 4860 tccctcgtgc gctctcctgt
tccgaccctg ccgcttaccg gatacctgtc cgcctttctc 4920 ccttcgggaa
gcgtggcgct ttctcaatgc tcacgctgta ggtatctcag ttcggtgtag 4980
gtcgttcgct ccaagctggg ctgtgtgcac gaaccccccg ttcagcccga ccgctgcgcc
5040 ttatccggta actatcgtct tgagtccaac ccggtaagac acgacttatc
gccactggca 5100 gcagccactg gtaacaggat tagcagagcg aggtatgtag
gcggtgctac agagttcttg 5160 aagtggtggc ctaactacgg ctacactaga
aggacagtat ttggtatctg cgctctgctg 5220 aagccagtta ccttcggaaa
aagagttggt agctcttgat ccggcaaaca aaccaccgct 5280 ggtagcggtg
gtttttttgt ttgcaagcag cagattacgc gcagaaaaaa aggatctcaa 5340
gaagatcctt tgatcttttc tacggggtct gacgctcagt ggaacgaaaa ctcacgttaa
5400 gggattttgg tcatgagatt atcaaaaagg atcttcacct agatcctttt
aaattaaaaa 5460 tgaagtttta aatcaatcta aagtatatat gagtaaactt
ggtctgacag ttaccaatgc 5520 ttaatcagtg aggcacctat ctcagcgatc
tgtctatttc gttcatccat agttgcctga 5580 ctccgggggg ggggggcgct
gaggtctgcc tcgtgaagaa ggtgttgctg actcatacca 5640 ggcctgaatc
gccccatcat ccagccagaa agtgagggag ccacggttga tgagagcttt 5700
gttgtaggtg gaccagttgg tgattttgaa cttttgcttt gccacggaac ggtctgcgtt
5760 gtcgggaaga tgcgtgatct gatccttcaa ctcagcaaaa gttcgattta
ttcaacaaag 5820 ccgccgtccc gtcaagtcag cgtaatgctc tgccagtgtt
acaaccaatt aaccaattct 5880 gattagaaaa actcatcgag catcaaatga
aactgcaatt tattcatatc aggattatca 5940 ataccatatt tttgaaaaag
ccgtttctgt aatgaaggag aaaactcacc gaggcagttc 6000 cataggatgg
caagatcctg gtatcggtct gcgattccga ctcgtccaac atcaatacaa 6060
cctattaatt tcccctcgtc aaaaataagg ttatcaagtg agaaatcacc atgagtgacg
6120 actgaatccg gtgagaatgg caaaagctta tgcatttctt tccagacttg
ttcaacaggc 6180 cagccattac gctcgtcatc aaaatcactc gcatcaacca
aaccgttatt cattcgtgat 6240 tgcgcctgag cgagacgaaa tacgcgatcg
ctgttaaaag gacaattaca aacaggaatc 6300 gaatgcaacc ggcgcaggaa
cactgccagc gcatcaacaa tattttcacc tgaatcagga 6360 tattcttcta
atacctggaa tgctgttttc ccggggatcg cagtggtgag taaccatgca 6420
tcatcaggag tacggataaa atgcttgatg gtcggaagag gcataaattc cgtcagccag
6480 tttagtctga ccatctcatc tgtaacatca ttggcaacgc tacctttgcc
atgtttcaga 6540 aacaactctg gcgcatcggg cttcccatac aatcgataga
ttgtcgcacc tgattgcccg 6600 acattatcgc gagcccattt atacccatat
aaatcagcat ccatgttgga atttaatcgc 6660 ggcctcgagc aagacgtttc
ccgttgaata tggctcataa caccccttgt attactgttt 6720 atgtaagcag
acagttttat tgttcatgat gatatatttt tatcttgtgc aatgtaacat 6780
cagagatttt gagacacaac gtggctttcc cccccccccc attattgaag catttatcag
6840 ggttattgtc tcatgagcgg atacatattt gaatgtattt agaaaaataa
acaaataggg 6900 gttccgcgca catttccccg aaaagtgcca cctgacgtct
aagaaaccat tattatcatg 6960 acattaacct ataaaaatag gcgtatcacg
aggccctttc gtc 7003 2 7073 DNA Artificial Sequence Description of
Artificial SequencePlasmid containing DNA for GP of Ebola Virus,
Sudan strain 2 tcgcgcgttt cggtgatgac ggtgaaaacc tctgacacat
gcagctcccg gagacggtca 60 cagcttgtct gtaagcggat gccgggagca
gacaagcccg tcagggcgcg tcagcgggtg 120 ttggcgggtg tcggggctgg
cttaactatg cggcatcaga gcagattgta ctgagagtgc 180 accatatgcg
gtgtgaaata ccgcacagat gcgtaaggag aaaataccgc atcagattgg 240
ctattggcca ttgcatacgt tgtatccata tcataatatg tacatttata ttggctcatg
300 tccaacatta ccgccatgtt gacattgatt attgactagt tattaatagt
aatcaattac 360 ggggtcatta gttcatagcc catatatgga gttccgcgtt
acataactta cggtaaatgg 420 cccgcctggc tgaccgccca acgacccccg
cccattgacg tcaataatga cgtatgttcc 480 catagtaacg ccaataggga
ctttccattg acgtcaatgg gtggagtatt tacggtaaac 540 tgcccacttg
gcagtacatc aagtgtatca tatgccaagt acgcccccta ttgacgtcaa 600
tgacggtaaa tggcccgcct ggcattatgc ccagtacatg accttatggg actttcctac
660 ttggcagtac atctacgtat tagtcatcgc tattaccatg gtgatgcggt
tttggcagta 720 catcaatggg cgtggatagc ggtttgactc acggggattt
ccaagtctcc accccattga 780 cgtcaatggg agtttgtttt ggcaccaaaa
tcaacgggac tttccaaaat gtcgtaacaa 840 ctccgcccca ttgacgcaaa
tgggcggtag gcgtgtacgg tgggaggtct atataagcag 900 agctcgttta
gtgaaccgtc agatcgcctg gagacgccat ccacgctgtt ttgacctcca 960
tagaagacac cgggaccgat ccagcctccg cggccgggaa cggtgcattg gaacgcggat
1020 tccccgtgcc aagagtgacg taagtaccgc ctatagactc tataggcaca
cccctttggc 1080 tcttatgcat gctatactgt ttttggcttg gggcctatac
acccccgctt ccttatgcta 1140 taggtgatgg tatagcttag cctataggtg
tgggttattg accattattg accactcccc 1200 tattggtgac gatactttcc
attactaatc cataacatgg ctctttgcca caactatctc 1260 tattggctat
atgccaatac tctgtccttc agagactgac acggactctg tatttttaca 1320
ggatggggtc ccatttatta tttacaaatt cacatataca acaacgccgt cccccgtgcc
1380 cgcagttttt attaaacata gcgtgggatc tccacgcgaa tctcgggtac
gtgttccgga 1440 catgggctct tctccggtag cggcggagct tccacatccg
agccctggtc ccatgcctcc 1500 agcggctcat ggtcgctcgg cagctccttg
ctcctaacag tggaggccag acttaggcac 1560 agcacaatgc ccaccaccac
cagtgtgccg cacaaggccg tggcggtagg gtatgtgtct 1620 gaaaatgagc
gtggagattg ggctcgcacg gctgacgcag atggaagact taaggcagcg 1680
gcagaagaag atgcaggcag ctgagttgtt gtattctgat aagagtcaga ggtaactccc
1740 gttgcggtgc tgttaacggt ggagggcagt gtagtctgag cagtactcgt
tgctgccgcg 1800 cgcgccacca gacataatag ctgacagact aacagactgt
tcctttccat gggtcttttc 1860 tgcagtcacc gtcgtcgaca cgtgtgatca
gatatcgcgg ccgctctagc tagatgcatg 1920 ctcgagcggc cgccagtgtg
atggatatct gcagaattct atcttcagga tctcgccatg 1980 gagggtctta
gcctactcca attgcccaga gataaatttc gaaaaagctc tttctttgtt 2040
tgggtcatca tcttatttca aaaggccttt tccatgcctt tgggtgttgt gaccaacagc
2100 actttagaag taacagagat tgaccagcta gtctgcaagg atcatcttgc
atcaactgac 2160 cagctgaaat cagttggtct caacctcgag gggagcggag
tatctactga tatcccatct 2220 gcgacaaagc gttggggctt cagatctggt
gtgcctcccc aagtggtcag ctatgaagca 2280 ggagaatggg ctgaaaattg
ctacaatctt gaaataaaga aaccggacgg gagcgaatgc 2340 ttacccccac
cgccggatgg tgtcagaggc tttccaaggt gccgctatgt tcacaaagcc 2400
caaggaaccg ggccctgccc gggtgactat gcctttcaca aggatggagc tttcttcctc
2460 tatgacaggc tggcttcaac tgtaatttac agaggagtca attttgctga
gggggtaatc 2520 gcattcttga tattggctaa accaaaggaa acgttccttc
aatcaccccc cattcgagag 2580 gcagcaaact acactgaaaa tacatcaagt
tactatgcca catcctactt ggagtacgaa 2640 atcgaaaatt ttggtgctca
acactccacg acccttttca aaattaacaa taatactttt 2700 gttcttctgg
acaggcccca cacgcctcag ttccttttcc agctgaatga taccattcaa 2760
cttcaccaac agttgagcaa cacaactggg aaactaattt ggacactaga tgctaatatc
2820 aatgctgata ttggtgaatg ggctttttgg gaaaataaaa aaatctctcc
gaacaactac 2880 gtggagaaga gctgtctttc gaaactttat cgctcaacga
gacagaagac gatgatgcga 2940 catcgtcgag aactacaaag ggaagaatct
ccgaccgggc caccaggaag tattcggacc 3000 tggttccaaa ggattcccct
gggatggttt cattgcacgt accagaaggg gaaacaacat 3060 tgccgtctca
gaattcgaca gaaggtcgaa gagtagatgt gaatactcag gaaactatca 3120
cagagacaac tgcaacaatc ataggcacta acggtaacaa catgcagatc tccaccatcg
3180 ggacaggact gagctccagc caaatcctga gttcctcacc gaccatggca
ccaagccctg 3240 agactcagac ctccacaacc tacacaccaa aactaccagt
gatgaccacc gaggaaccaa 3300 caacaccacc gagaaactct cctggctcaa
caacagaagc acccactctc accaccccag 3360 agaatataac aacagcggtt
aaaactgttt gggcacaaga gtccacaagc aacggtctaa 3420 taacttcaac
agtaacaggt attcttggga gccttggact tcgaaaacgc agcagaagac 3480
aagttaacac cagggccacg ggtaaatgca atcccaactt acactactgg actgcacaag
3540 aacaacataa tgctgctggg attgcctgga tcccgtactt tggaccgggt
gcagaaggca 3600 tatacactga aggccttatg cacaaccaaa atgccttagt
ctgtggactc agacaacttg 3660 caaatgaaac aactcaagct ctgcagcttt
tcttaagggc cacgacggag ctgcggacat 3720 ataccatact caataggaag
gccatagatt tccttctgcg acgatggggc gggacatgta 3780 ggatcctggg
accagattgt tgcattgagc cacatgattg gaccaaaaac atcactgata 3840
aaatcaacca aatcatccat gatttcatcg acaacccttt acccaatcag gataatgatg
3900 ataattggtg gacgggctgg agacagtgga tccctgcagg aataggcatt
actggaatta 3960 ttattgcaat cattgctctt ctttgcgtct gcaagctgct
ttgttgaata tcagaattcc 4020 agcactggcg gccgttacta gtggatccga
gctcggatcc aagctctaga ccaggcgcct 4080 ggatccagat ctgctgtgcc
ttctagttgc cagccatctg ttgtttgccc ctcccccgtg 4140 ccttccttga
ccctggaagg tgccactccc actgtccttt cctaataaaa tgaggaaatt 4200
gcatcgcatt gtctgagtag gtgtcattct attctggggg gtggggtggg gcagcacagc
4260 aagggggagg attgggaaga caatagcagg catgctgggg atgcggtggg
ctctatgggt 4320 acccaggtgc tgaagaattg acccggttcc tcctgggcca
gaaagaagca ggcacatccc 4380 cttctctgtg acacaccctg tccacgcccc
tggttcttag ttccagcccc actcatagga 4440 cactcatagc tcaggagggc
tccgccttca atcccacccg ctaaagtact tggagcggtc 4500 tctccctccc
tcatcagccc accaaaccaa acctagcctc caagagtggg aagaaattaa 4560
agcaagatag gctattaagt gcagagggag agaaaatgcc tccaacatgt gaggaagtaa
4620 tgagagaaat catagaattt cttccgcttc ctcgctcact gactcgctgc
gctcggtcgt 4680 tcggctgcgg cgagcggtat cagctcactc aaaggcggta
atacggttat ccacagaatc 4740 aggggataac gcaggaaaga acatgtgagc
aaaaggccag caaaaggcca ggaaccgtaa 4800 aaaggccgcg ttgctggcgt
ttttccatag gctccgcccc cctgacgagc atcacaaaaa 4860 tcgacgctca
agtcagaggt ggcgaaaccc gacaggacta taaagatacc aggcgtttcc 4920
ccctggaagc tccctcgtgc gctctcctgt tccgaccctg ccgcttaccg gatacctgtc
4980 cgcctttctc ccttcgggaa gcgtggcgct ttctcaatgc tcacgctgta
ggtatctcag 5040 ttcggtgtag gtcgttcgct ccaagctggg ctgtgtgcac
gaaccccccg ttcagcccga 5100 ccgctgcgcc ttatccggta actatcgtct
tgagtccaac ccggtaagac acgacttatc 5160 gccactggca gcagccactg
gtaacaggat tagcagagcg aggtatgtag gcggtgctac 5220 agagttcttg
aagtggtggc ctaactacgg ctacactaga aggacagtat ttggtatctg 5280
cgctctgctg aagccagtta ccttcggaaa aagagttggt agctcttgat ccggcaaaca
5340 aaccaccgct ggtagcggtg gtttttttgt ttgcaagcag cagattacgc
gcagaaaaaa 5400 aggatctcaa gaagatcctt tgatcttttc tacggggtct
gacgctcagt ggaacgaaaa 5460 ctcacgttaa gggattttgg tcatgagatt
atcaaaaagg atcttcacct agatcctttt 5520 aaattaaaaa tgaagtttta
aatcaatcta aagtatatat gagtaaactt ggtctgacag 5580 ttaccaatgc
ttaatcagtg aggcacctat ctcagcgatc tgtctatttc gttcatccat 5640
agttgcctga ctccgggggg ggggggcgct gaggtctgcc tcgtgaagaa ggtgttgctg
5700 actcatacca ggcctgaatc gccccatcat ccagccagaa agtgagggag
ccacggttga 5760 tgagagcttt gttgtaggtg gaccagttgg tgattttgaa
cttttgcttt gccacggaac 5820 ggtctgcgtt gtcgggaaga tgcgtgatct
gatccttcaa ctcagcaaaa gttcgattta 5880 ttcaacaaag ccgccgtccc
gtcaagtcag cgtaatgctc tgccagtgtt acaaccaatt 5940 aaccaattct
gattagaaaa actcatcgag catcaaatga aactgcaatt tattcatatc 6000
aggattatca ataccatatt tttgaaaaag ccgtttctgt aatgaaggag aaaactcacc
6060 gaggcagttc cataggatgg caagatcctg gtatcggtct gcgattccga
ctcgtccaac 6120 atcaatacaa cctattaatt tcccctcgtc aaaaataagg
ttatcaagtg agaaatcacc 6180 atgagtgacg actgaatccg gtgagaatgg
caaaagctta tgcatttctt tccagacttg 6240 ttcaacaggc cagccattac
gctcgtcatc aaaatcactc gcatcaacca aaccgttatt 6300 cattcgtgat
tgcgcctgag cgagacgaaa tacgcgatcg ctgttaaaag gacaattaca 6360
aacaggaatc gaatgcaacc ggcgcaggaa cactgccagc gcatcaacaa tattttcacc
6420 tgaatcagga tattcttcta atacctggaa tgctgttttc ccggggatcg
cagtggtgag 6480 taaccatgca tcatcaggag tacggataaa atgcttgatg
gtcggaagag gcataaattc 6540 cgtcagccag tttagtctga ccatctcatc
tgtaacatca ttggcaacgc tacctttgcc 6600 atgtttcaga aacaactctg
gcgcatcggg cttcccatac aatcgataga ttgtcgcacc 6660 tgattgcccg
acattatcgc gagcccattt atacccatat aaatcagcat ccatgttgga 6720
atttaatcgc ggcctcgagc aagacgtttc ccgttgaata tggctcataa caccccttgt
6780 attactgttt atgtaagcag acagttttat tgttcatgat gatatatttt
tatcttgtgc 6840 aatgtaacat cagagatttt gagacacaac gtggctttcc
cccccccccc attattgaag 6900 catttatcag ggttattgtc tcatgagcgg
atacatattt gaatgtattt agaaaaataa 6960 acaaataggg gttccgcgca
catttccccg aaaagtgcca cctgacgtct aagaaaccat 7020 tattatcatg
acattaacct ataaaaatag gcgtatcacg aggccctttc gtc 7073 3 7285 DNA
Artificial Sequence Description of Artificial SequencePlasmid
containing DNA of GP of Ebola Virus, Zaire strain 3 tcgcgcgttt
cggtgatgac ggtgaaaacc tctgacacat gcagctcccg gagacggtca 60
cagcttgtct gtaagcggat gccgggagca gacaagcccg tcagggcgcg tcagcgggtg
120 ttggcgggtg tcggggctgg cttaactatg cggcatcaga gcagattgta
ctgagagtgc 180 accatatgcg gtgtgaaata ccgcacagat gcgtaaggag
aaaataccgc atcagattgg 240 ctattggcca ttgcatacgt tgtatccata
tcataatatg tacatttata ttggctcatg 300 tccaacatta ccgccatgtt
gacattgatt attgactagt tattaatagt aatcaattac 360 ggggtcatta
gttcatagcc catatatgga gttccgcgtt acataactta cggtaaatgg 420
cccgcctggc tgaccgccca acgacccccg cccattgacg tcaataatga cgtatgttcc
480 catagtaacg ccaataggga ctttccattg acgtcaatgg gtggagtatt
tacggtaaac 540 tgcccacttg gcagtacatc aagtgtatca tatgccaagt
acgcccccta ttgacgtcaa 600 tgacggtaaa
tggcccgcct ggcattatgc ccagtacatg accttatggg actttcctac 660
ttggcagtac atctacgtat tagtcatcgc tattaccatg gtgatgcggt tttggcagta
720 catcaatggg cgtggatagc ggtttgactc acggggattt ccaagtctcc
accccattga 780 cgtcaatggg agtttgtttt ggcaccaaaa tcaacgggac
tttccaaaat gtcgtaacaa 840 ctccgcccca ttgacgcaaa tgggcggtag
gcgtgtacgg tgggaggtct atataagcag 900 agctcgttta gtgaaccgtc
agatcgcctg gagacgccat ccacgctgtt ttgacctcca 960 tagaagacac
cgggaccgat ccagcctccg cggccgggaa cggtgcattg gaacgcggat 1020
tccccgtgcc aagagtgacg taagtaccgc ctatagactc tataggcaca cccctttggc
1080 tcttatgcat gctatactgt ttttggcttg gggcctatac acccccgctt
ccttatgcta 1140 taggtgatgg tatagcttag cctataggtg tgggttattg
accattattg accactcccc 1200 tattggtgac gatactttcc attactaatc
cataacatgg ctctttgcca caactatctc 1260 tattggctat atgccaatac
tctgtccttc agagactgac acggactctg tatttttaca 1320 ggatggggtc
ccatttatta tttacaaatt cacatataca acaacgccgt cccccgtgcc 1380
cgcagttttt attaaacata gcgtgggatc tccacgcgaa tctcgggtac gtgttccgga
1440 catgggctct tctccggtag cggcggagct tccacatccg agccctggtc
ccatgcctcc 1500 agcggctcat ggtcgctcgg cagctccttg ctcctaacag
tggaggccag acttaggcac 1560 agcacaatgc ccaccaccac cagtgtgccg
cacaaggccg tggcggtagg gtatgtgtct 1620 gaaaatgagc gtggagattg
ggctcgcacg gctgacgcag atggaagact taaggcagcg 1680 gcagaagaag
atgcaggcag ctgagttgtt gtattctgat aagagtcaga ggtaactccc 1740
gttgcggtgc tgttaacggt ggagggcagt gtagtctgag cagtactcgt tgctgccgcg
1800 cgcgccacca gacataatag ctgacagact aacagactgt tcctttccat
gggtcttttc 1860 tgcagtcacc gtcgtcgaca cgtgtgatca gatatcgcgg
ccgctctaga ccaggcgcct 1920 ggatcgatcc gcgatgaaga ttaagccgac
agtgagcgta atcttcatct ctcttagatt 1980 atttgttttc cagagtaggg
gtcgtcaggt ccttttcaat cgtgtaacca aaataaactc 2040 cactagaagg
atattgtggg gcaacaacac aatgggcgtt acaggaatat tgcagttacc 2100
tcgtgatcga ttcaagagga catcattctt tctttgggta attatccttt tccaaagaac
2160 attttccatc ccacttggag tcatccacaa tagcacatta caggttagtg
atgtcgacaa 2220 actagtttgt cgtgacaaac tgtcatccac aaatcaattg
agatcagttg gactgaatct 2280 cgaagggaat ggagtggcaa ctgacgtgcc
atctgcaact aaaagatggg gcttcaggtc 2340 cggtgtccca ccaaaggtgg
tcaattatga agctggtgaa tgggctgaaa actgctacaa 2400 tcttgaaatc
aaaaaacctg acgggagtga gtgtctacca gcagcgccag acgggattcg 2460
gggcttcccc cggtgccggt atgtgcacaa agtatcagga acgggaccgt gtgccggaga
2520 ctttgccttc cataaagagg gtgctttctt cctgtatgat cgacttgctt
ccacagttat 2580 ctaccgagga acgactttcg ctgaaggtgt cgttgcattt
ctgatactgc cccaagctaa 2640 gaaggacttc ttcagctcac accccttgag
agagccggtc aatgcaacgg aggacccgtc 2700 tagtggctac tattctacca
caattagata tcaggctacc ggttttggaa ccaatgagac 2760 agagtacttg
ttcgaggttg acaatttgac ctacgtccaa cttgaatcaa gattcacacc 2820
acagtttctg ctccagctga atgagacaat atatacaagt gggaaaagga gcaataccac
2880 gggaaaacta atttggaagg tcaaccccga aattgataca acaatcgggg
agtgggcctt 2940 ctgggaaact aaaaaaaacc tcactagaaa aattcgcagt
gaagagttgt ctttcacagt 3000 tgtatcaaac ggagccaaaa acatcagtgg
tcagagtccg gcgcgaactt cttccgaccc 3060 agggaccaac acaacaactg
aagaccacaa aatcatggct tcagaaaatt cctctgcaat 3120 ggttcaagtg
cacagtcaag gaagggaagc tgcagtgtcg catctaacaa cccttgccac 3180
aatctccacg agtccccaat ccctcacaac caaaccaggt ccggacaaca gcacccataa
3240 tacacccgtg tataaacttg acatctctga ggcaactcaa gttgaacaac
atcaccgcag 3300 aacagacaac gacagcacag cctccgacac tccctctgcc
acgaccgcag ccggaccccc 3360 aaaagcagag aacaccaaca cgagcaagag
cactgacttc ctggaccccg ccaccacaac 3420 aagtccccaa aaccacagcg
agaccgctgg caacaacaac actcatcacc aagataccgg 3480 agaagagagt
gccagcagcg ggaagctagg cttaattacc aatactattg ctggagtcgc 3540
aggactgatc acaggcggga gaagaactcg aagagaagca attgtcaatg ctcaacccaa
3600 atgcaaccct aatttacatt actggactac tcaggatgaa ggtgctgcaa
tcggactggc 3660 ctggatacca tatttcgggc cagcagccga gggaatttac
atagaggggc taatgcacaa 3720 tcaagatggt ttaatctgtg ggttgagaca
gctggccaac gagacgactc aagctcttca 3780 actgttcctg agagccacaa
ctgagctacg caccttttca atcctcaacc gtaaggcaat 3840 tgatttcttg
ctgcagcgat ggggcggcac atgccacatt ctgggaccgg actgctgtat 3900
cgaaccacat gattggacca agaacataac agacaaaatt gatcagatta ttcatgattt
3960 tgttgataaa acccttccgg accaggggga caatgacaat tggtggacag
gatggagaca 4020 atggataccg gcaggtattg gagttacagg cgttataatt
gcagttatcg ctttattctg 4080 tatatgcaaa tttgtctttt agtttttctt
cagattgctt catggaaaag ctcagcctca 4140 aatcaatgaa accaggattt
aattatatgg attacttgaa tctaagatta cttgacaaat 4200 gataatataa
tacactggag ctttaaacat agccaatgtg attctaactc ctttaaactc 4260
acagttaatc ataaacaagg tttggtaccg agctcgaatt atctgctgtg ccttctagtt
4320 gccagccatc tgttgtttgc ccctcccccg tgccttcctt gaccctggaa
ggtgccactc 4380 ccactgtcct ttcctaataa aatgaggaaa ttgcatcgca
ttgtctgagt aggtgtcatt 4440 ctattctggg gggtggggtg gggcagcaca
gcaaggggga ggattgggaa gacaatagca 4500 ggcatgctgg ggatgcggtg
ggctctatgg gtacccaggt gctgaagaat tgacccggtt 4560 cctcctgggc
cagaaagaag caggcacatc cccttctctg tgacacaccc tgtccacgcc 4620
cctggttctt agttccagcc ccactcatag gacactcata gctcaggagg gctccgcctt
4680 caatcccacc cgctaaagta cttggagcgg tctctccctc cctcatcagc
ccaccaaacc 4740 aaacctagcc tccaagagtg ggaagaaatt aaagcaagat
aggctattaa gtgcagaggg 4800 agagaaaatg cctccaacat gtgaggaagt
aatgagagaa atcatagaat ttcttccgct 4860 tcctcgctca ctgactcgct
gcgctcggtc gttcggctgc ggcgagcggt atcagctcac 4920 tcaaaggcgg
taatacggtt atccacagaa tcaggggata acgcaggaaa gaacatgtga 4980
gcaaaaggcc agcaaaaggc caggaaccgt aaaaaggccg cgttgctggc gtttttccat
5040 aggctccgcc cccctgacga gcatcacaaa aatcgacgct caagtcagag
gtggcgaaac 5100 ccgacaggac tataaagata ccaggcgttt ccccctggaa
gctccctcgt gcgctctcct 5160 gttccgaccc tgccgcttac cggatacctg
tccgcctttc tcccttcggg aagcgtggcg 5220 ctttctcaat gctcacgctg
taggtatctc agttcggtgt aggtcgttcg ctccaagctg 5280 ggctgtgtgc
acgaaccccc cgttcagccc gaccgctgcg ccttatccgg taactatcgt 5340
cttgagtcca acccggtaag acacgactta tcgccactgg cagcagccac tggtaacagg
5400 attagcagag cgaggtatgt aggcggtgct acagagttct tgaagtggtg
gcctaactac 5460 ggctacacta gaaggacagt atttggtatc tgcgctctgc
tgaagccagt taccttcgga 5520 aaaagagttg gtagctcttg atccggcaaa
caaaccaccg ctggtagcgg tggttttttt 5580 gtttgcaagc agcagattac
gcgcagaaaa aaaggatctc aagaagatcc tttgatcttt 5640 tctacggggt
ctgacgctca gtggaacgaa aactcacgtt aagggatttt ggtcatgaga 5700
ttatcaaaaa ggatcttcac ctagatcctt ttaaattaaa aatgaagttt taaatcaatc
5760 taaagtatat atgagtaaac ttggtctgac agttaccaat gcttaatcag
tgaggcacct 5820 atctcagcga tctgtctatt tcgttcatcc atagttgcct
gactccgggg ggggggggcg 5880 ctgaggtctg cctcgtgaag aaggtgttgc
tgactcatac caggcctgaa tcgccccatc 5940 atccagccag aaagtgaggg
agccacggtt gatgagagct ttgttgtagg tggaccagtt 6000 ggtgattttg
aacttttgct ttgccacgga acggtctgcg ttgtcgggaa gatgcgtgat 6060
ctgatccttc aactcagcaa aagttcgatt tattcaacaa agccgccgtc ccgtcaagtc
6120 agcgtaatgc tctgccagtg ttacaaccaa ttaaccaatt ctgattagaa
aaactcatcg 6180 agcatcaaat gaaactgcaa tttattcata tcaggattat
caataccata tttttgaaaa 6240 agccgtttct gtaatgaagg agaaaactca
ccgaggcagt tccataggat ggcaagatcc 6300 tggtatcggt ctgcgattcc
gactcgtcca acatcaatac aacctattaa tttcccctcg 6360 tcaaaaataa
ggttatcaag tgagaaatca ccatgagtga cgactgaatc cggtgagaat 6420
ggcaaaagct tatgcatttc tttccagact tgttcaacag gccagccatt acgctcgtca
6480 tcaaaatcac tcgcatcaac caaaccgtta ttcattcgtg attgcgcctg
agcgagacga 6540 aatacgcgat cgctgttaaa aggacaatta caaacaggaa
tcgaatgcaa ccggcgcagg 6600 aacactgcca gcgcatcaac aatattttca
cctgaatcag gatattcttc taatacctgg 6660 aatgctgttt tcccggggat
cgcagtggtg agtaaccatg catcatcagg agtacggata 6720 aaatgcttga
tggtcggaag aggcataaat tccgtcagcc agtttagtct gaccatctca 6780
tctgtaacat cattggcaac gctacctttg ccatgtttca gaaacaactc tggcgcatcg
6840 ggcttcccat acaatcgata gattgtcgca cctgattgcc cgacattatc
gcgagcccat 6900 ttatacccat ataaatcagc atccatgttg gaatttaatc
gcggcctcga gcaagacgtt 6960 tcccgttgaa tatggctcat aacacccctt
gtattactgt ttatgtaagc agacagtttt 7020 attgttcatg atgatatatt
tttatcttgt gcaatgtaac atcagagatt ttgagacaca 7080 acgtggcttt
cccccccccc ccattattga agcatttatc agggttattg tctcatgagc 7140
ggatacatat ttgaatgtat ttagaaaaat aaacaaatag gggttccgcg cacatttccc
7200 cgaaaagtgc cacctgacgt ctaagaaacc attattatca tgacattaac
ctataaaaat 7260 aggcgtatca cgaggccctt tcgtc 7285 4 7272 DNA
Artificial Sequence Description of Artificial SequencePlasmid
containing DNA for soluble GP of Ebola Virus, Zaire strain 4
tcgcgcgttt cggtgatgac ggtgaaaacc tctgacacat gcagctcccg gagacggtca
60 cagcttgtct gtaagcggat gccgggagca gacaagcccg tcagggcgcg
tcagcgggtg 120 ttggcgggtg tcggggctgg cttaactatg cggcatcaga
gcagattgta ctgagagtgc 180 accatatgcg gtgtgaaata ccgcacagat
gcgtaaggag aaaataccgc atcagattgg 240 ctattggcca ttgcatacgt
tgtatccata tcataatatg tacatttata ttggctcatg 300 tccaacatta
ccgccatgtt gacattgatt attgactagt tattaatagt aatcaattac 360
ggggtcatta gttcatagcc catatatgga gttccgcgtt acataactta cggtaaatgg
420 cccgcctggc tgaccgccca acgacccccg cccattgacg tcaataatga
cgtatgttcc 480 catagtaacg ccaataggga ctttccattg acgtcaatgg
gtggagtatt tacggtaaac 540 tgcccacttg gcagtacatc aagtgtatca
tatgccaagt acgcccccta ttgacgtcaa 600 tgacggtaaa tggcccgcct
ggcattatgc ccagtacatg accttatggg actttcctac 660 ttggcagtac
atctacgtat tagtcatcgc tattaccatg gtgatgcggt tttggcagta 720
catcaatggg cgtggatagc ggtttgactc acggggattt ccaagtctcc accccattga
780 cgtcaatggg agtttgtttt ggcaccaaaa tcaacgggac tttccaaaat
gtcgtaacaa 840 ctccgcccca ttgacgcaaa tgggcggtag gcgtgtacgg
tgggaggtct atataagcag 900 agctcgttta gtgaaccgtc agatcgcctg
gagacgccat ccacgctgtt ttgacctcca 960 tagaagacac cgggaccgat
ccagcctccg cggccgggaa cggtgcattg gaacgcggat 1020 tccccgtgcc
aagagtgacg taagtaccgc ctatagactc tataggcaca cccctttggc 1080
tcttatgcat gctatactgt ttttggcttg gggcctatac acccccgctt ccttatgcta
1140 taggtgatgg tatagcttag cctataggtg tgggttattg accattattg
accactcccc 1200 tattggtgac gatactttcc attactaatc cataacatgg
ctctttgcca caactatctc 1260 tattggctat atgccaatac tctgtccttc
agagactgac acggactctg tatttttaca 1320 ggatggggtc ccatttatta
tttacaaatt cacatataca acaacgccgt cccccgtgcc 1380 cgcagttttt
attaaacata gcgtgggatc tccacgcgaa tctcgggtac gtgttccgga 1440
catgggctct tctccggtag cggcggagct tccacatccg agccctggtc ccatgcctcc
1500 agcggctcat ggtcgctcgg cagctccttg ctcctaacag tggaggccag
acttaggcac 1560 agcacaatgc ccaccaccac cagtgtgccg cacaaggccg
tggcggtagg gtatgtgtct 1620 gaaaatgagc gtggagattg ggctcgcacg
gctgacgcag atggaagact taaggcagcg 1680 gcagaagaag atgcaggcag
ctgagttgtt gtattctgat aagagtcaga ggtaactccc 1740 gttgcggtgc
tgttaacggt ggagggcagt gtagtctgag cagtactcgt tgctgccgcg 1800
cgcgccacca gacataatag ctgacagact aacagactgt tcctttccat gggtcttttc
1860 tgcagtcacc gtcgtcgaca cgtgtgatca gatatcgcgg ccgctctaga
ccaggcgcct 1920 ggatcgaatt gatgaagatt aagccgacag tgagcgtaat
cttcatctct cttagattat 1980 ttgttttcca gagtaggggt cgtcaggtcc
ttttcaatcg tgtaaccaaa ataaactcca 2040 ctagaaggat attgtggggc
aacaacacaa tgggcgttac aggaatattg cagttacctc 2100 gtgatcgatt
caagaggaca tcattctttc tttgggtaat tatccttttc caaagaacat 2160
tttccatccc acttggagtc atccacaata gcacattaca ggttagtgat gtcgacaaac
2220 tagtttgtcg tgacaaactg tcatccacaa atcaattgag atcagttgga
ctgaatctcg 2280 aagggaatgg agtggcaact gacgtgccat ctgcaactaa
aagatggggc ttcaggtccg 2340 gtgtcccacc aaaggtggtc aattatgaag
ctggtgaatg ggctgaaaac tgctacaatc 2400 ttgaaatcaa aaaacctgac
gggagtgagt gtctaccagc agcgccagac gggattcggg 2460 gcttcccccg
gtgccggtat gtgcacaaag tatcaggaac gggaccgtgt gccggagact 2520
ttgccttcca taaagagggt gctttcttcc tgtatgatcg acttgcttcc acagttatct
2580 accgaggaac gactttcgct gaaggtgtcg ttgcatttct gatactgccc
caagctaaga 2640 aggacttctt cagctcacac cccttgagag agccggtcaa
tgcaacggag gacccgtcta 2700 gtggctacta ttctaccaca attagatatc
aggctaccgg ttttggaacc aatgagacag 2760 agtacttgtt cgaggttgac
aatttgacct acgtccaact tgaatcaaga ttcacaccac 2820 agtttctgct
ccagctgaat gagacaatat atacaagtgg gaaaaggagc aataccacgg 2880
gaaaactaat ttggaaggtc aaccccgaaa ttgatacaac aatcggggag tgggccttct
2940 gggaaactaa aaaaacctca ctagaaaaat tcgcagtgaa gagttgtctt
tcacagttgt 3000 atcaaacgga gccaaaaaca tcagtggtca gagtccggcg
cgaacttctt ccgacccagg 3060 gaccaacaca acaactgaag accacaaaat
catggcttca gaaaattcct ctgcaatggt 3120 tcaagtgcac agtcaaggaa
gggaagctgc agtgtcgcat ctaacaaccc ttgccacaat 3180 ctccacgagt
ccccaatccc tcacaaccaa accaggtccg gacaacagca cccataatac 3240
acccgtgtat aaacttgaca tctctgaggc aactcaagtt gaacaacatc accgcagaac
3300 agacaacgac agcacagcct ccgacactcc ctctgccacg accgcagccg
gacccccaaa 3360 agcagagaac accaacacga gcaagagcac tgacttcctg
gaccccgcca ccacaacaag 3420 tccccaaaac cacagcgaga ccgctggcaa
caacaacact catcaccaag ataccggaga 3480 agagagtgcc agcagcggga
agctaggctt aattaccaat actattgctg gagtcgcagg 3540 actgatcaca
ggcgggagaa gaactcgaag agaagcaatt gtcaatgctc aacccaaatg 3600
caaccctaat ttacattact ggactactca ggatgaaggt gctgcaatcg gactggcctg
3660 gataccatat ttcgggccag cagccgaggg aatttacata gaggggctaa
tgcacaatca 3720 agatggttta atctgtgggt tgagacagct ggccaacgag
acgactcaag ctcttcaact 3780 gttcctgaga gccacaactg agctacgcac
cttttcaatc ctcaaccgta aggcaattga 3840 tttcttgctg cagcgatggg
gcggcacatg ccacattctg ggaccggact gctgtatcga 3900 accacatgat
tggaccaaga acataacaga caaaattgat cagattattc atgattttgt 3960
tgataaaacc cttccggacc agggggacaa tgacaattgg tggacaggat ggagacaatg
4020 gataccggca ggtattggag ttacaggcgt tataattgca gttatcgctt
tattctgtat 4080 atgcaaattt gtcttttagt ttttcttcag attgcttcat
ggaaaagctc agcctcaaat 4140 caatgaaacc aggatttaat tatatggatt
acttgaatct aagattactt gacaaatgat 4200 aatataatac actggagctt
taaacatagc caatgtgatt ctaactcctt taaactcaca 4260 gttaatcata
aacaaggttt ggaattgatc tgctgtgcct tctagttgcc agccatctgt 4320
tgtttgcccc tcccccgtgc cttccttgac cctggaaggt gccactccca ctgtcctttc
4380 ctaataaaat gaggaaattg catcgcattg tctgagtagg tgtcattcta
ttctgggggg 4440 tggggtgggg cagcacagca agggggagga ttgggaagac
aatagcaggc atgctgggga 4500 tgcggtgggc tctatgggta cccaggtgct
gaagaattga cccggttcct cctgggccag 4560 aaagaagcag gcacatcccc
ttctctgtga cacaccctgt ccacgcccct ggttcttagt 4620 tccagcccca
ctcataggac actcatagct caggagggct ccgccttcaa tcccacccgc 4680
taaagtactt ggagcggtct ctccctccct catcagccca ccaaaccaaa cctagcctcc
4740 aagagtggga agaaattaaa gcaagatagg ctattaagtg cagagggaga
gaaaatgcct 4800 ccaacatgtg aggaagtaat gagagaaatc atagaatttc
ttccgcttcc tcgctcactg 4860 actcgctgcg ctcggtcgtt cggctgcggc
gagcggtatc agctcactca aaggcggtaa 4920 tacggttatc cacagaatca
ggggataacg caggaaagaa catgtgagca aaaggccagc 4980 aaaaggccag
gaaccgtaaa aaggccgcgt tgctggcgtt tttccatagg ctccgccccc 5040
ctgacgagca tcacaaaaat cgacgctcaa gtcagaggtg gcgaaacccg acaggactat
5100 aaagatacca ggcgtttccc cctggaagct ccctcgtgcg ctctcctgtt
ccgaccctgc 5160 cgcttaccgg atacctgtcc gcctttctcc cttcgggaag
cgtggcgctt tctcaatgct 5220 cacgctgtag gtatctcagt tcggtgtagg
tcgttcgctc caagctgggc tgtgtgcacg 5280 aaccccccgt tcagcccgac
cgctgcgcct tatccggtaa ctatcgtctt gagtccaacc 5340 cggtaagaca
cgacttatcg ccactggcag cagccactgg taacaggatt agcagagcga 5400
ggtatgtagg cggtgctaca gagttcttga agtggtggcc taactacggc tacactagaa
5460 ggacagtatt tggtatctgc gctctgctga agccagttac cttcggaaaa
agagttggta 5520 gctcttgatc cggcaaacaa accaccgctg gtagcggtgg
tttttttgtt tgcaagcagc 5580 agattacgcg cagaaaaaaa ggatctcaag
aagatccttt gatcttttct acggggtctg 5640 acgctcagtg gaacgaaaac
tcacgttaag ggattttggt catgagatta tcaaaaagga 5700 tcttcaccta
gatcctttta aattaaaaat gaagttttaa atcaatctaa agtatatatg 5760
agtaaacttg gtctgacagt taccaatgct taatcagtga ggcacctatc tcagcgatct
5820 gtctatttcg ttcatccata gttgcctgac tccggggggg gggggcgctg
aggtctgcct 5880 cgtgaagaag gtgttgctga ctcataccag gcctgaatcg
ccccatcatc cagccagaaa 5940 gtgagggagc cacggttgat gagagctttg
ttgtaggtgg accagttggt gattttgaac 6000 ttttgctttg ccacggaacg
gtctgcgttg tcgggaagat gcgtgatctg atccttcaac 6060 tcagcaaaag
ttcgatttat tcaacaaagc cgccgtcccg tcaagtcagc gtaatgctct 6120
gccagtgtta caaccaatta accaattctg attagaaaaa ctcatcgagc atcaaatgaa
6180 actgcaattt attcatatca ggattatcaa taccatattt ttgaaaaagc
cgtttctgta 6240 atgaaggaga aaactcaccg aggcagttcc ataggatggc
aagatcctgg tatcggtctg 6300 cgattccgac tcgtccaaca tcaatacaac
ctattaattt cccctcgtca aaaataaggt 6360 tatcaagtga gaaatcacca
tgagtgacga ctgaatccgg tgagaatggc aaaagcttat 6420 gcatttcttt
ccagacttgt tcaacaggcc agccattacg ctcgtcatca aaatcactcg 6480
catcaaccaa accgttattc attcgtgatt gcgcctgagc gagacgaaat acgcgatcgc
6540 tgttaaaagg acaattacaa acaggaatcg aatgcaaccg gcgcaggaac
actgccagcg 6600 catcaacaat attttcacct gaatcaggat attcttctaa
tacctggaat gctgttttcc 6660 cggggatcgc agtggtgagt aaccatgcat
catcaggagt acggataaaa tgcttgatgg 6720 tcggaagagg cataaattcc
gtcagccagt ttagtctgac catctcatct gtaacatcat 6780 tggcaacgct
acctttgcca tgtttcagaa acaactctgg cgcatcgggc ttcccataca 6840
atcgatagat tgtcgcacct gattgcccga cattatcgcg agcccattta tacccatata
6900 aatcagcatc catgttggaa tttaatcgcg gcctcgagca agacgtttcc
cgttgaatat 6960 ggctcataac accccttgta ttactgttta tgtaagcaga
cagttttatt gttcatgatg 7020 atatattttt atcttgtgca atgtaacatc
agagattttg agacacaacg tggctttccc 7080 ccccccccca ttattgaagc
atttatcagg gttattgtct catgagcgga tacatatttg 7140 aatgtattta
gaaaaataaa caaatagggg ttccgcgcac atttccccga aaagtgccac 7200
ctgacgtcta agaaaccatt attatcatga cattaaccta taaaaatagg cgtatcacga
7260 ggccctttcg tc 7272
* * * * *